Loading organizations...
§ Private Profile · New York City, NY, USA
AI-driven software company offering automated, clinical-grade ECG interpretation for cardiology and remote patient monitoring.
Based in New York City, AccurKardia develops device-agnostic, artificial intelligence-powered software designed for automated, clinical-grade electrocardiogram interpretation across various medical monitoring devices. The company operates a business-to-business model, providing software-as-a-medical-device licensing and application programming interface integrations directly to remote patient monitoring systems, telehealth platforms, and wearable device manufacturers. Operating with a team of approximately ten employees, the enterprise secured 510(k) clearance from the Food and Drug Administration in July 2023 for its flagship cloud-based analysis system, AccurECG. The platform combines proprietary algorithms and non-artificial intelligence techniques to deliver near-real-time analytics, while the startup also develops additional research products including AK-AVS and AK+ Guard. Furthermore, the organization gained notable industry recognition by winning the Heart Rhythm Society digital health pitch competition in May 2022. AccurKardia was founded in 2019 by Juan C. Jimenez and Naveen Srinivas.
AccurKardia has raised $2.7M across 1 funding round.
AccurKardia has raised $2.7M in total across 1 funding round.
AccurKardia has raised $2.7M in total across 1 funding round.
AccurKardia's investors include Popular.
AccurKardia has raised $2.7M across 1 funding round. Most recently, it raised $2.7M Seed in June 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 20, 2023 | $2.7M Seed | Popular | — | Announced |